University of Illinois Cancer Center: Summer CME SeriesSession 2 - General Oncology | June 18, 2025Post Test | Evaluation and Claim Credit UICMES | Session 2 | Post-Test | June 18, 2025 June 18, 2025University of Illinois Cancer Center Summer CME SeriesSession 2: General Oncology Please enter your information: First Name * Last Name * Degree * Institution * Email * City * State * 1. In early-stage non-small cell lung cancer (NSCLC), adjuvant osimertinib is indicated for patients with: * A. ALK rearrangement B. EGFR exon 19 or 21 mutations C. KRAS G12C mutation D. MET amplification 2. Which of the following statements best describes CNS metastases in cancer patients? * A. CNS metastases only occur in late-stage cancers B. Radiation is no longer used for CNS metastases C. Multimodal approaches are often required D. ADCs are the only effective therapy 3. The use of ADCs in solid tumors is expanding because of: * A. Lower manufacturing costs B. Nonspecific cytotoxicity C. Precision targeting of tumor antigens D. Universal biomarker expression 4. Which agent has most recently shown improved overall survival in metastatic pancreatic cancer in combination regimens? * A. Erlotinib B. Irinotecan liposome (nal-IRI) C. FOLFIRINOX D. Pembrolizumab 5. (Patient Case). A 62-year-old man presents with metastatic NSCLC and confirmed EGFR exon 21 mutation. After 12 months of first-line osimertinib, he develops brain metastases. What is the best next step in management? * A. Switch to chemotherapy B. Repeat biopsy and molecular testing for resistance C. Add immune checkpoint inhibitor D. Continue osimertinib without changes Submit Number
